MetLife Investment Management’s Definium Therapeutics DFTX Stock Holding History

MetLife Investment Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.03M	Buy	54,261 +1,681	+3%	+$28.5K	0.01%	1381
2025 Q4	$704K	Buy	52,580 +3,384	+7%	+$41.9K	﹤0.01%	1623
2025 Q3	$580K	Hold	49,196	–	–	﹤0.01%	1734
2025 Q2	$319K	Hold	49,196	–	–	﹤0.01%	1919
2025 Q1	$288K	Sell	49,196 -466	-0.9%	-$3.34K	﹤0.01%	1996
2024 Q4	$346K	Buy	49,662 +7,113	+17%	+$48.9K	﹤0.01%	1995
2024 Q3	$242K	Buy	+42,549	New	+$296K	﹤0.01%	2189
2022 Q2	–	Sell	-9,745	Closed	-$162K	–	2890
2022 Q1	$162K	Buy	9,745 +524	+6%	+$9.09K	﹤0.01%	2476
2021 Q4	$191K	Buy	9,221 +3,070	+50%	+$98K	﹤0.01%	2076
2021 Q3	$215K	Sell	6,151 -2,244	-27%	-$97K	﹤0.01%	2051
2021 Q2	$434K	Buy	+8,395	New	+$441K	﹤0.01%	1651

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MetLife Investment Management's DFTX Position: Q1 2026 in Review

MetLife Investment Management increased its Definium Therapeutics (DFTX) stake by 3.2% in Q1 2026, buying an estimated $28.5K and bringing the position to 54,261 shares worth $1.03M. The position accounts for 0.01% of the portfolio, ranked #1381.

MetLife Investment Management first reported a position in DFTX in Q2 2021 and has held it in 11 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

MetLife Investment Management held 54,261 shares of Definium Therapeutics worth $1.03M as of Q1 2026.
MetLife Investment Management bought 1,681 Definium Therapeutics shares in Q1 2026, an estimated $28.5K.
Definium Therapeutics made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1381 holding.
MetLife Investment Management first reported a position in Definium Therapeutics in Q2 2021 and has held it in 11 quarters since.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.